Steven Kregel

This study identifies METTL3 as a non-enzymatic AR co-regulator that promotes prostate cancer proliferation by supporting AR-driven transcriptional programs.

This study identifies SOX2 and FOXA1 as a transcriptional partnership driving proliferation and lineage plasticity in therapy-resistant prostate cancer.

This study optimizes a PROTAC to degrade IDO1 with high potency in GBM cells, showing sustained degradation via the ubiquitin-proteasome system.

This study investigates how a novel SERM, T6I-29, downregulates DKK1 in Y537S ESR1 mutant breast cancer cells and identifies DKK1 as a potential therapeutic target.

This paper introduces a biologically informed deep learning model for prostate cancer classification and identifies molecular drivers of treatment resistance.